Search details
1.
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
N Engl J Med
; 383(10): 931-943, 2020 09 03.
Article
in English
| MEDLINE | ID: mdl-32469185
2.
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study).
Cancer Immunol Immunother
; 72(1): 91-99, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-35729418
3.
The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours.
Acta Oncol
; 60(12): 1597-1603, 2021 Dec.
Article
in English
| MEDLINE | ID: mdl-34549686
4.
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.
Ann Rheum Dis
; 77(3): 393-398, 2018 03.
Article
in English
| MEDLINE | ID: mdl-29146737
5.
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Lancet
; 387(10026): 1415-1426, 2016 Apr 02.
Article
in English
| MEDLINE | ID: mdl-26777916
6.
Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.
Target Oncol
; 18(4): 585-591, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-37310660
7.
Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study).
J Immunother
; 2023 Oct 09.
Article
in English
| MEDLINE | ID: mdl-37807621
8.
Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.
RMD Open
; 9(4)2023 11 29.
Article
in English
| MEDLINE | ID: mdl-38030233
9.
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B.
Cell Rep Med
; 4(11): 101280, 2023 11 21.
Article
in English
| MEDLINE | ID: mdl-37944528
10.
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
JAMA Oncol
; 9(9): 1260-1266, 2023 09 01.
Article
in English
| MEDLINE | ID: mdl-37270698
11.
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
J Thorac Oncol
; 18(12): 1731-1742, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37597750
12.
Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice.
Thorac Cancer
; 13(15): 2248-2252, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35715960
13.
Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non-small cell lung cancer: A retrospective study.
Thorac Cancer
; 13(9): 1391-1400, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35434866
14.
A Prospective Study to Detect Immune Checkpoint Inhibitors Associated With Myocarditis Among Patients Treated for Lung Cancer.
Front Cardiovasc Med
; 9: 878211, 2022.
Article
in English
| MEDLINE | ID: mdl-35734278
15.
Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.
Eur J Cancer
; 172: 85-95, 2022 Sep.
Article
in English
| MEDLINE | ID: mdl-35759814
16.
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.
Clin Lung Cancer
; 23(4): 320-332, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35466070
17.
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
Clin Cancer Res
; 28(6): 1117-1126, 2022 03 15.
Article
in English
| MEDLINE | ID: mdl-34789481
18.
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events.
Eur J Cancer
; 157: 474-484, 2021 11.
Article
in English
| MEDLINE | ID: mdl-34649118
19.
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.
JCO Precis Oncol
; 4: 829-840, 2020 Nov.
Article
in English
| MEDLINE | ID: mdl-35050757
20.
Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients.
Clin Lung Cancer
; 21(5): e497-e510, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32605892